510(k) · Cleared
ClearedDimension Vista Dbil Flex Reagent Cartridge, Model K2125
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Dade Behring, Inc. · CIG Diazo Colorimetry, Bilirubin
Cleared on Aug 29, 2006 as substantially equivalent to K862359 (E.I. Dupont DE Nemours & Co., Inc., 1986) after a 61-day review. Its family tree reaches back 1 generation to 1986.
- Decided
- Aug 29, 2006
- Review
- 61 days
- Class
- Class II
- Product code
- CIG
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 1 generation to K862359 (1986). No later device cites it as a predicate yet.
- Root · 1 generation backK862359 Meth./Cali./Intru. Check for the Dimension SystemE.I. Dupont DE Nemours & Co., Inc. · 1986 · Recalled
- This deviceK061839 Dimension Vista Dbil Flex Reagent Cartridge, Model K2125Dade Behring, Inc. · 2006
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −1 | K862359 | Meth./Cali./Intru. Check for the Dimension System | E.I. Dupont DE Nemours & Co., Inc. | 1986 | 2 |
| 0 (this device) | K061839 | Dimension Vista Dbil Flex Reagent Cartridge, Model K2125 | Dade Behring, Inc. | 2006 | — |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in CIG? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new CIG device
- #1 K251998 Atellica CH Diazo Total Bilirubin (D_TBil)score 11.8 · 4 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K862359 | Meth./Cali./Intru. Check for the Dimension SystemSummary page 1…® reagent cartridge FDA Classification Name: Bilimbin (total or direct) test system Predicate Device: Dade Behring DBIL Flex® reagent cartridge (k862359) Device Description: Diazotized sulfanilic acid is formed by combining sodium nitrite and sulfanilic acid at low pH. The sample… | 1986 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- Its one ancestor has a recall.
- 3 other devices also cite its predicate K862359.
How does its category compare?
All CIG devicesCIG Diazo Colorimetry, Bilirubin: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · CIG
2in 2023
2026 to Oct 25, outlined.
Median 510(k) review, days · CIG
64in 2013
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · CIG
1in 2019
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · CIG
52in 2025
MAUDE reports naming product code CIG, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 1 | — | 0 | 2 |
| 2008 | 3 | 199 | 0 | 8 |
| 2009 | 2 | — | 3 | 3 |
| 2010 | 1 | — | 0 | 6 |
| 2011 | 2 | — | 0 | 38 |
| 2012 | 0 | — | 0 | 14 |
| 2013 | 5 | 64 | 3 | 8 |
| 2014 | 0 | — | 0 | 3 |
| 2015 | 1 | — | 0 | 7 |
| 2016 | 0 | — | 0 | 4 |
| 2017 | 1 | — | 0 | 11 |
| 2018 | 0 | — | 0 | 23 |
| 2019 | 1 | — | 1 | 25 |
| 2020 | 0 | — | 0 | 31 |
| 2021 | 0 | — | 0 | 22 |
| 2022 | 1 | — | 0 | 26 |
| 2023 | 2 | — | 0 | 34 |
| 2024 | 0 | — | 0 | 39 |
| 2025 | 0 | — | 0 | 52 |
| 2026 | 1 | — | 0 | — |
What is it indicated for?
The DBIL method is an in vitro diagnostic test for the quantitative measurement of direct
(conjugated) bilirubin in human serum and plasma on the Dimension Vista System.
Measurements of direct bilirubin are used in the diagnosis and treatment of liver, hemolytic,
hematological and metabolic disorders, including hepatitis and gall bladder disease.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K061839 · printed Nov 5, 2026
Cite this page
510(k) Report. “K061839: Dimension Vista Dbil Flex Reagent Cartridge, Model K2125.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K061839
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026